Nu-Med Plus (NUMD) Return on Capital Employed (2013 - 2025)
Nu-Med Plus (NUMD) reported Return on Capital Employed of 17.95% for Q4 2025, down 1132.0% on a YoY basis from 1.74% in Q4 2024, and down 4.81% sequentially from 18.86% in Q3 2025.
Nu-Med Plus (NUMD) Return on Capital Employed (2013 - 2025) Analysis & Trends
Nu-Med Plus (NUMD) has 13 years of Return on Capital Employed data on file, last reported at 17.95% in Q4 2025.
- For the quarter ending Q4 2025, Return on Capital Employed fell 1132.0% year-over-year to 17.95%; the trailing twelve-month figure through Dec 2025 stood at 17.95% (down 1132.0% YoY), and the FY2025 full-year result was 18.09%, down 1163.0% from the prior year.
- Return on Capital Employed fell to 17.95% in Q4 2025, from 18.86% in the prior quarter.
- In the past five years, Return on Capital Employed ranged from a high of 2413.52% in Q3 2021 to a low of 1624.23% in Q2 2021.
- A 5-year average of 115.02% and a median of 63.99% in 2023 frame the typical range for Return on Capital Employed.
- Across the five-year window, Return on Capital Employed soared 610587 bps in 2021 and slumped 230581 bps in 2022, its largest moves.
- Tracing NUMD's Return on Capital Employed over 5 years: stood at 712.47% in 2021, then plunged by 75 bps to 179.98% in 2022, then sank by 54 bps to 82.21% in 2023, then slumped by 64 bps to 29.27% in 2024, then sank by 39 bps to 17.95% in 2025.
- Business Quant data shows NUMD's Return on Capital Employed at 17.95% in Q4 2025, 18.86% in Q3 2025, and 22.49% in Q2 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | ROCE (Qtr) |
|---|---|---|---|---|---|
| 1 | Abbott Laboratories | 183.58 Bn | 176.28 Bn | 6.27 Bn | 9.61% |
| 2 | Stryker | 129.01 Bn | 126.13 Bn | 3.81 Bn | 12.24% |
| 3 | Medtronic | 108.52 Bn | 99.30 Bn | 6.41 Bn | 8.02% |
| 4 | Boston Scientific | 68.67 Bn | 67.22 Bn | 3.61 Bn | 9.62% |
| 5 | Edwards Lifesciences | 48.33 Bn | 44.66 Bn | 1.29 Bn | 11.13% |
| 6 | Dexcom | 28.34 Bn | 27.23 Bn | 750.30 Mn | 24.24% |
| 7 | GE HealthCare Technologies | 28.07 Bn | 25.79 Bn | 1.98 Bn | 9.30% |
| 8 | Smith & Nephew | 26.89 Bn | 26.31 Bn | - | - |
| 9 | Koninklijke Philips | 24.12 Bn | 21.00 Bn | 2.07 Bn | 8.38% |
| 10 | Nu-Med Plus | 1.67 Mn | 1.67 Mn | - | 17.95% |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | 17.95% |
| Sep 30, 2025 | 18.86% |
| Jun 30, 2025 | 22.49% |
| Mar 31, 2025 | 26.38% |
| Dec 31, 2024 | 29.27% |
| Sep 30, 2024 | 54.03% |
| Jun 30, 2024 | 57.31% |
| Mar 31, 2024 | 68.61% |
| Dec 31, 2023 | 82.21% |
| Sep 30, 2023 | 59.38% |
| Jun 30, 2023 | 109.78% |
| Mar 31, 2023 | 184.57% |
| Dec 31, 2022 | 179.98% |
| Sep 30, 2022 | 107.71% |
| Jun 30, 2022 | 140.87% |
| Mar 31, 2022 | 298.17% |
| Dec 31, 2021 | 712.47% |
| Sep 30, 2021 | 2,413.52% |
| Jun 30, 2021 | -1,624.23% |
| Mar 31, 2021 | -658.87% |